RegenxbioRGNX
Market Cap: $626M
About: Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Employees: 344
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
54% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 48
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
0.32% less ownership
Funds ownership: 89.18% [Q1] → 88.86% (-0.32%) [Q2]
2% less funds holding
Funds holding: 185 [Q1] → 181 (-4) [Q2]
13% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 30
18% less call options, than puts
Call options by funds: $850K | Put options by funds: $1.04M
44% less capital invested
Capital invested by funds: $920M [Q1] → $512M (-$408M) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Yi Chen 40% 1-year accuracy 56 / 140 met price target | 208%upside $39 | Buy Reiterated | 4 Sept 2024 |
Barclays Gena Wang 32% 1-year accuracy 8 / 25 met price target | 295%upside $50 | Overweight Maintained | 5 Aug 2024 |
HC Wainwright & Co. Yi Chen 40% 1-year accuracy 56 / 140 met price target | 208%upside $39 | Buy Maintained | 5 Aug 2024 |
HC Wainwright & Co. Yi Chen 40% 1-year accuracy 56 / 140 met price target | 200%upside $38 | Buy Reiterated | 20 Jun 2024 |
Financial journalist opinion
Based on 4 articles about RGNX published over the past 30 days